Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi

Executive Summary

Third biosimilar approved in US brings another iteration of FDA thinking on labeling and naming; etanercept-szzs, which references Amgen's Enbrel, suggests agency might be backtracking on its suffix policy.

Advertisement

Related Content

Sandoz’s Erelzi: Biosimilar Pediatric Labeling Strayed From Enbrel
Sandoz Tested Erelzi’s Suffix On Multiple Fronts
Biosimilar Labeling: Should FDA Just Throw Up Its Hands And Finalize Guidance?
Biosimilar Advisory Committee Reviews: Necessity Or Nuisance?
Biosimilar Naming: FDA Asked Celltrion For Two Kinds Of Suffixes
Biosimilars' Pediatric Pressures Could Push Them Toward Interchangeability
FDA's Biosimilar Suffix 'Error': Molehill Withdrawn But Mountain Coming?
Biosimilar Template Revisited: Inflectra Approval Binds And Separates From Remicade
FDA Biosimilar Naming Policy Takes Middle-Of-The-Road Approach
How To Label A Biosimilar? Copy The Reference Product, FDA Told Sandoz

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119039

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel